Fate Therapeutics, Inc.
NASDAQ:FATE
Overview | Financials
Company Name | Fate Therapeutics, Inc. |
Symbol | FATE |
Currency | USD |
Price | 1.255 |
Market Cap | 142,936,970 |
Dividend Yield | 0% |
52-week-range | 1.04 - 8.83 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. J. Scott Wolchko |
Website | https://www.fatetherapeutics.com |
An error occurred while fetching data.
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia;
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD